What they were paid
UroGen Pharma Director Compensation Table · the one fiscal year held| Fiscal year | Cash fees | Stock awards | Option awards | Other | Total |
|---|---|---|---|---|---|
| FY2025 | $58,478 | $156,000 | $168,743 | $0 | $383,221 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: UroGen Pharma Ltd. DEF 14A filed April 30, 2026, accession 0001437749-26-014237, and prior-year filings. Open the filing on EDGAR.
Committees
FY2025 · as the proxy prints themNominating/Governance · Compliance (Chair)
The rest of the UroGen Pharma board
FY2025 · as the company reported each| Director | Role | FY2025 total |
|---|---|---|
| Arie Belldegrun, M.D | Chair of the Board | $537,486 |
| Cynthia M. Butitta | Independent Director | $389,743 |
| Daniel G. Wildman | Independent Director | — |
| Elizabeth Barrett | Director | $0 |
| Leana S. Wen, M.D., M.Sc | Independent Director | $392,243 |
| Stuart Holden, M.D | Independent Director | $382,243 |
The full UroGen Pharma compensation record
free company briefThis page is one director within UroGen Pharma's record. The company brief lists every named executive and director, each linking to their own page.
Velarion Pro: every company page, peer tools and exports, one seat